Skip to main content
رجوع
Watch Compare

LIGAND PHARMACEUTICALS INC

جودة البيانات: 100%
مُدرج أيضًا باسم LGNXZ Nasdaq LGNYZ Nasdaq LGNZZ Nasdaq
LGNDZ
Nasdaq Manufacturing Chemicals
KWD 0.00
▲ KWD 0.00 (6.67%)
القيمة السوقية: 32,470.0
السعر
KWD 0.00
القيمة السوقية
32,470.0
نطاق اليوم
KWD 0.00 — KWD 0.00
نطاق 52 أسبوعًا
KWD 0.00 — KWD 0.00
حجم التداول
32,000
فتح KWD 0.00
متوسط 50 يوم / 200 يوم
—
متوسط 50 يوم / 200 يوم
—

Quick Summary

النقاط الرئيسية

Revenue declined -0.83% annually over 5 years
ROE of 13.99% — decent returns on equity
Net margin of 46.42% shows strong profitability
Generating 48.91 M in free cash flow
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 61.23%
Capital efficient — spends only 0.17% of revenue on capex

النمو

Revenue Growth (5Y)
-0.83%
أقل من متوسط القطاع (1.82%)
Revenue (1Y)60.40%
Earnings (1Y)N/A
FCF Growth (3Y)3.05%

الجودة

Return on Equity
13.99%
أعلى من متوسط القطاع (-53.41%)
ROIC2.76%
Net Margin46.42%
Op. Margin15.29%

الأمان

Debt / Equity
N/A
Current Ratio24.69
Interest Coverage8.70

التقييم

PE (TTM)
0.00
أعلى من متوسط القطاع (-1.48)
P/B Ratio0.00
EV/EBITDA-1.86
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E 0.0 -1.5
P/B 0.0 1.6
ROE % 14.0 -53.4
Net Margin % 46.4 -41.5
Rev Growth 5Y % -0.8 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 60.40% Revenue Growth (3Y) 42.88%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 54.48%
Revenue Growth (5Y) -0.83% Earnings Growth (5Y) 21.48%
Profitability
Revenue (TTM) 268.09 M Net Income (TTM) 124.45 M
ROE 13.99% ROA 10.26%
Gross Margin N/A Operating Margin 15.29%
Net Margin 46.42% Free Cash Flow (TTM) 48.91 M
ROIC 2.76% FCF Growth (3Y) 3.05%
Safety
Debt / Equity N/A Current Ratio 24.69
Interest Coverage 8.70 Asset Turnover 0.22
Working Capital 723.38 M Tangible Book Value 615.10 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 0.00 Forward P/E N/A
P/B Ratio 0.00 P/S Ratio 0.00
PEG Ratio 0.00 Forward PEG N/A
EV/EBITDA -1.86 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 150622.11%
Market Cap 32,470.0 Enterprise Value -139.34 M
Per Share
EPS (Diluted TTM) 6.13 Revenue / Share 13.21
FCF / Share 2.41 OCF / Share 2.43
EPS CAGR (1Y) N/A EPS CAGR (5Y) 16.66%
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0.17% FCF Conversion 39.30%
SBC-Adj. FCF 1.16 M Growth Momentum 61.23

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 268.09 M 167.13 M 131.31 M 196.25 M 277.13 M
Net Income 124.45 M -4.03 M 52.15 M -33.36 M 57.14 M
EPS (Diluted) 6.13 -0.22 2.94 -1.98 3.31
Gross Profit — — — — —
Operating Income 41.00 M -22.61 M 11.94 M 3.04 M 78.90 M
EBITDA — — — — —
R&D Expenses 81.18 M 21.43 M 24.54 M 36.08 M 69.01 M
SG&A Expenses — — — — —
D&A 33.78 M 35.24 M 36.52 M 51.53 M 51.07 M
Interest Expense 4.72 M 3.04 M 656,000.0 1.80 M 19.63 M
Income Tax 34.51 M 6.55 M 9.84 M 41.23 M -9.84 M

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.56 B 941.77 M 787.22 M 762.67 M 1.30 B
Total Liabilities 543.43 M 111.34 M 86.30 M 165.18 M 476.43 M
Shareholders' Equity 1.02 B 830.44 M 700.91 M 597.49 M 821.16 M
Total Debt — — — — —
Cash & Equivalents 174.93 M 72.31 M 22.95 M 45.01 M 19.52 M
Current Assets 832.27 M 331.56 M 237.43 M 263.60 M 464.75 M
Current Liabilities 37.45 M 37.11 M 16.78 M 98.81 M 41.67 M